Zeitschrift für Naturforschung C,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 4, 2024
Aging
results
into
disruptive
physiological
functioning
and
cellular
processes
that
affect
the
composition
structure
of
plasma
membrane.
The
membrane
is
major
regulator
ionic
homeostasis
regulates
transporters
exchangers.
Coenzyme
Q
Cellular and Molecular Life Sciences,
Journal Year:
2025,
Volume and Issue:
82(1)
Published: Jan. 8, 2025
Diabetes
is
a
primary
contributor
to
diabetic
cardiomyopathy
(DbCM),
which
marked
by
metabolic
imbalances
such
as
elevated
blood
glucose
and
lipid
levels,
leading
significant
structural
functional
alterations
in
the
myocardium.
Elevated
free
fatty
acids
(FFAs)
hyperglycemia
play
critical
roles
DbCM
development,
with
FFAs
inducing
insulin
resistance
cardiomyocytes
promoting
accumulation,
resulting
oxidative
stress
fibrosis.
Current
research
suggests
that
glucagon-like
peptide-1
(GLP-1)
receptor
agonists
may
effectively
mitigate
DbCM,
although
an
effective
treatment
for
this
condition
remains
elusive,
precise
mechanisms
of
protective
effect
are
not
fully
understood.
In
study,
we
aimed
replicate
glucolipotoxic
conditions
treating
differentiated
H9c2
cells
high
acids.
Additionally,
model
was
induced
mice
through
high-fat
diets.
Both
vitro
vivo
models
were
used
investigate
effects
liraglutide
on
elucidate
its
underlying
molecular
mechanisms.
Our
findings
indicate
significantly
reduces
droplet
(LD)
formation
myocardial
fibrosis,
evidenced
decreased
expression
fibrosis
markers,
including
TGF-β1
collagen
types
I
III.
Liraglutide
also
enhanced
AMP-activated
protein
kinase
(AMPK)
activation,
improved
mitochondrial
function,
increased
antioxidant
gene
expression,
signaling,
reduced
stress.
These
results
demonstrate
potential
therapeutic
role
managing
diabetes-related
cardiac
complications,
offering
comprehensive
approach
improving
outcomes
patients
diabetes.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(1), P. 134 - 134
Published: Jan. 20, 2025
Diabetes
mellitus
(DM)
is
a
multifaceted
disorder
with
pandemic
spread
and
remarkable
burden
of
cardiovascular
mortality
morbidity.
Diabetic
cardiomyopathy
(DBCM)
has
been
increasingly
recognized
as
the
development
cardiac
dysfunction,
which
accompanied
by
heart
failure
(HF)
symptoms
in
absence
obvious
reasons
like
ischemic
disease,
hypertension,
or
valvulopathies.
Several
pathophysiological
mechanisms
have
proposed,
including
metabolic
disorders
(e.g.,
glycation
products),
oxidative
stress,
low-grade
inflammation,
mitochondrial
etc.,
should
guide
new
therapeutic
strategies.
Up
to
now,
HF
treatment
not
differed
between
patients
without
diabetes,
limits
expected
benefits
despite
high
risk
former
group.
However,
DBCM
may
require
different
management,
prioritize
anti-diabetic
medications
testing
other
novel
therapies.
This
review
aims
appraise
challenges
prospectives
individualized
pharmaceutical
therapy
for
DBCM.
Cardiovascular Diabetology,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: March 20, 2025
Increasing
evidence
highlights
the
critical
role
of
Piezo1
in
cardiovascular
diseases,
with
its
expression
upregulated
diabetic
heart.
However,
involvement
pathogenesis
cardiomyopathy
(DCM)
remains
unclear.
This
study
aims
to
elucidate
regulatory
mitochondrial
dynamics
within
context
DCM
and
investigate
underlying
mechanisms.
We
constructed
cardiac-specific
knockout
(Piezo1∆Myh6)
mice.
Type
1
diabetes
was
induced
using
streptozotocin
(STZ)
injection
while
type
2
established
through
a
high-fat
diet
combined
STZ.
Echocardiography
assessed
left
ventricular
function,
histological
evaluations
used
HE
Masson
staining
examine
cardiac
pathology
Piezo1fl/fl
controls,
Piezo1∆Myh6
Mitochondrial
function
including
oxygen
species
level,
morphology,
respiration
rate
were
also
assessed.
Our
findings
revealed
that
myocardium
mice
high-glucose-treated
cells.
Cardiac-specific
improved
dysfunction
ameliorated
fibrosis
Moreover,
deficiency
attenuated
impairment.
exhibited
increased
calpain
activity
excessive
fission
mediated
by
Drp1
obvious
reduced
fusion;
however,
restored
levels
dysfunction.
These
observations
corroborated
H9C2
cells
neonatal
mouse
cardiomyocytes.
phosphorylation
ERK1/2
vivo
vitro.
or
treatment
inhibitor
function.
provides
first
is
elevated
modulation
dynamics,
which
reversed
deficiency.
Thus,
inhibition
may
provide
promising
therapeutic
strategy
for
DCM.
In
cardiomyocytes
mice,
Ca2+
entry
upregulates
activity,
phosphorylated
level
Drp1.
Therefore,
shown
hearts.
Whereas,
cardiomyocyte-specific
alleviates
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 11, 2025
Diabetes
mellitus
(DM)
is
a
chronic
endocrine
and
metabolic
disorder
characterized
by
persistent
hyperglycemia
that
poses
serious
threats
to
human
health
quality
of
life.
The
morbidity,
disability,
mortality
rates
cardiovascular
complications
stemming
from
are
primary
factors
affecting
the
lifespan
patients
with
diabetes.
Currently,
there
no
cure
for
DM.
Standard
biomedical
treatments
mostly
control
symptoms
using
insulin
injections
or
oral
hypoglycemic
drugs.
Although
effect
standard
therapy
remarkable,
its
long-term
use
prone
toxic
side
effects.
Numerous
studies
have
recently
found
Traditional
Chinese
Medicine
(TCM)
has
strong
advantages
in
prevention
treatment
DM
(DACC).
collection,
processing,
preparation
clinical
TCM
guided
theory
follow
“holistic
concept.”
Multiple
components,
pathways,
targets
form
basis
treating
multiple
parts
organs
body
simultaneously.
mainly
derived
natural
medicines
their
processed
products
fewer
clinically
used
as
compound
prescriptions,
botanical
drugs,
monomers.
TCM,
either
independently
combination
treatments,
shown
unique
therapeutic
advantages.
This
review
aimed
explore
reported
mechanisms
action
DACC.
These
findings
will
aid
optimization
current
formation
schedule
integrated
treatments.
Medicina,
Journal Year:
2024,
Volume and Issue:
60(12), P. 1986 - 1986
Published: Dec. 2, 2024
The
increasing
prevalence
of
both
type
2
diabetes
mellitus
and
heart
failure
has
underscored
the
urgent
need
for
optimized
therapeutic
strategies
that
address
complex
interplay
between
these
conditions.
Dipeptidyl
peptidase-4
(DPP-4)
inhibitors
have
emerged
as
a
popular
class
glucose-lowering
agents
due
to
their
favorable
glycemic
effects,
safety
profile,
potential
cardiovascular
benefits.
However,
impact
DPP-4
on
outcomes
in
patients
with
remains
contentious,
conflicting
evidence
from
clinical
trials
observational
studies.
This
review
critically
examines
current
use
coexisting
failure,
focusing
pharmacodynamics,
safety,
efficacy
outcomes.
We
explore
physiological
mechanisms
by
which
may
influence
risk,
including
modulation
inflammation,
oxidative
stress,
myocardial
fibrosis.
Clinical
such
SAVOR-TIMI
53,
EXAMINE,
TECOS
are
evaluated
provide
comprehensive
analysis
inhibitors'
effects
hospitalization
mortality,
events
diabetic
patients.
While
some
suggest
an
increased
risk
HF
hospitalizations
specific
(e.g.,
saxagliptin),
others
report
neutral
raising
questions
about
versus
individual
drug
characteristics
within
this
group.
Additionally,
we
discrepancies
related
patient
demographics,
phenotype,
comorbid
conditions
risk-benefit
profile.
Comparative
insights
into
alternative
therapies
SGLT2
GLP-1
receptor
agonists
also
provided,
highlighting
implications
treatment
selection
high-risk
population.
In
summary,
synthesizes
available
aiming
guide
clinicians
making
informed
decisions.
remain
viable
option
management,
caution
is
warranted
advanced
future
research
essential
refine
patient-specific
guidelines.
Journal of Population Therapeutics and Clinical Pharmacology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 14, 2024
Hu
et
al
specified
that
HFpEF
is
undoubtedly
a
major
as
well
diverse
structural
type
of
heart
failure
affecting
nearly
half
the
new
patients
identified
globally.
Compared
to
HFrEF,
similar
situation
observed
in
where
underlying
mechanisms
disease
are
broader
and
it
extremely
difficult
manage
disorder.
This
study
found
that,
despite
optimal
medical
therapy,
with
had
marked
symptom
burden,
high
hospitalization
rate,
reduced
health-related
quality
life,
indicating
need
for
better
therapeutic
management
strategies.
The
systematic
review
current
treatment
diagnosed
will
focus
on
effectiveness
treatments.
In
this
regard,
aims
determine
knowledge
gaps
evident
within
available
literature
proposals
subsequent
clinical
investigations.
search
incorporated
databases
PubMed,
Cochrane
Library,
Embase,
Web
Science,
adhering
PRISMA
protocol.
Article
inclusion
was
guided
by
specific
conditions
namely,
trials,
observation
studies,
systemic
reviews
comparing
treatments
HFpEF.
Data
extraction
assessment
were
performed
using
standard
tools
made
very
reliable
valid.
Overall,
45
closed
trials
met
eligibility
criterion.
Previous
pharmacological
including
ARNIs,
SGLT2i
MRAs
modest
effect
decreasing
CV
hospitalizations
but
neutral
small
all-cause
mortality.
Frequent
devices
such
lifestyle
changes
exercise
protocols
seen
upgrade
functional
ability
besides
increasing
life
However,
none
these
highly
effective,
always
necessitating
combination
individualized
approach.
conclusion,
therapy
presents
itself
several
options
have
shown
promising
results
complexity
disorder
due
wide
divergence
its
presentation.
These
suggest
pharmacotherapy
should
be
further
complemented
modifications
improve
functioning
patients.
More
work
has
done
precisely
define
individual
approaches
addressing
heterogeneous
pathophysiology
set
clear
recommendations.